AstraZeneca

LONDON, 10-12-2015 — /EuropaWire/ — AstraZeneca today announced plans to test a digital support service for women undergoing treatment for recurrent platinum-sensitive high-grade ovarian cancer in clinical trials of cediranib plus olaparib. Voluntis has developed the service in close clinical … Read the full press release →

LONDON, 31-8-2015 — /EuropaWire/ — Over 20 scientific abstracts from AstraZeneca’s cardiovascular and metabolic disease portfolio will be presented at this year’s European Society of Cardiology (ESC) Congress 2015 in London, including five oral presentations. Data being presented will focus … Read the full press release →

Princeton, New Jersey, 30-7-2015 — /EuropaWire/ — Sandoz today announced the US market introduction of its budesonide inhalation suspension, a generic version of Pulmicort Respules® (budesonide) inhalation suspension 1 mg strength by AstraZeneca LP. Sandoz’s budesonide inhalation suspension product is indicated … Read the full press release →

Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa®(vandetanib) from AstraZeneca Paris, France,  30-7-2015 — /EuropaWire/ — Sanofi and its subsidiary Genzyme announced today that it has entered into a definitive agreement with AstraZeneca to acquire Caprelsa® (vandetanib), a … Read the full press release →

LONDON, 2-6-2015 — /EuropaWire/ — AstraZeneca and MedImmune, the company’s global biologics research and development arm, today presented encouraging results from their novel combination-focused immuno-oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015. Overall, data indicated … Read the full press release →

LONDON, 4-5-2015 — /EuropaWire/ — AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) and granted Priority Review for BRILINTA® (ticagrelor) tablets for patients with a history of heart attack. … Read the full press release →